TOKYO -- Japan's Fujifilm Holdings said it was "extremely disappointed," after government officials deferred approval of its Avigan treatment for COVID-19, setting back the company's global ambitions for the drug.
Fujifilm said it followed the required protocols in a clinical test that is facing questions over its credibility, after Japan's health ministry said it was difficult to clearly determine Avigan's efficacy from the available data.
